文献速递临床试验与 GCP基础与转化研究

血液生物标志物作为遗忘型轻度认知障碍有氧运动与认知训练治疗反应的替代终点:ACT试验血液生物标志物研究方案

Blood biomarkers as surrogate endpoints of treatment responses to aerobic exercise and cognitive training (ACT) in amnestic mild cognitive impairment: the blood biomarkers study protocol of a randomized controlled trial (the ACT Trial).
PubMed 文献 · Trials · 2020-01-06

本研究基于ACT试验(一项单盲、多中心、2×2析因II期RCT,n=128),纳入120例遗忘型轻度认知障碍患者,测量基线和3、6、12、18个月血液生物标志物。目的是确定6个月干预对血液生物标志物的影响,并评估其作为18个月认知和MRI脑标志物反应替代终点的价值。

要点

  • 血液生物标志物可能成为AD预防试验中成本低、微创的替代终点。
  • 研究嵌套于ACT试验,评估有氧运动、认知训练及联合干预对血液标志物的影响。
  • 探索血液标志物预测18个月认知和脑MRI标志物反应的能力。

核心结论

  • 研究旨在识别能追踪aMCI患者认知下降或AD相关脑萎缩的血液生物标志物。

研究设计与样本

  • 基于ACT试验(单盲、多中心、2×2析因II期RCT,n=128)的血液生物标志物研究。
  • 纳入120例aMCI患者,在基线及3、6、12、18个月测量血液神经病理、神经退行和神经营养标志物。

关键数值与推荐

  • 干预为6个月有氧运动、认知训练或联合干预。
  • 主要目标包括确定6个月干预对血液标志物的影响及评估其预测18个月认知反应。
  • 探索性目标为评估血液标志物预测18个月脑MRI标志物反应。

临床怎么用

  • 若验证成功,血液标志物可用于AD痴呆预防试验中作为经济微创的替代终点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Alzheimer's disease (AD) is an epidemic with tremendous public health impacts because there are currently no disease-modifying therapeutics. Randomized controlled trials (RCTs) for prevention of AD dementia often use clinical endpoints that take years to manifest (e.g., cognition) or surrogate endpoints that are costly or invasive (e.g., magnetic resonance imaging [MRI]). Blood biomarkers represent a clinically applicable alternative surrogate endpoint for RCTs that would be both cost-effective and minimally invasive, but little is known about their value as surrogate endpoints for treatment responses in the prevention of AD dementia. METHODS: The objective of this study is to investigate blood neuropathological, neurodegenerative, and neurotrophic biomarkers as surrogate endpoints for treatment responses to three interventions in older adults with amnestic mild cognitive impairment (aMCI, a prodromal stage of AD): aerobic exercise, cognitive training, and combined aerobic exercise and cognitive training (ACT). We chose these three sets of biomarkers for their unique mechanistic associations with AD pathology, neurodegeneration and neurogenesis. This study is built on the ACT Trial (1R01AG055469), a single-blinded, multi-site, 2 × 2 factorial phase II RCT that examines the synergistic effects of a 6-month ACT intervention on cognition and MRI biomarkers (AD-signature cortical thickness and hippocampal volume) (n = 128). In this ACT Trial blood biomarkers study, we will enroll 120 ACT Trial participants with aMCI and measure blood biomarkers at baseline and at 3, 6, 12, and 18 months. The goals are to (1) determine the effect of interventions on blood biomarkers over 6 months, (2) evaluate blood biomarkers as surrogate endpoints for predicting cognitive responses to interventions over 18 months, and (3, exploratory) examine blood biomarkers as surrogate endpoints for predicting brain MRI biomarker responses to interventions over 18 months. DISCUSSION: This study aims to identify new blood biomarkers that can track cognitive decline or AD-related brain atrophy among patients with aMCI subjected to a regimen of aerobic exercise and cognitive training. Findings from this study will drive the further use of blood biomarkers in developing effective prevention and treatment strategies for AD dementia. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03313895. Registered on 18 October 2017.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Li D, Mielke MM, Bell WR, et al. Blood biomarkers as surrogate endpoints of treatment responses to aerobic exercise and cognitive training (ACT) in amnestic mild cognitive impairment: the blood biomarkers study protocol of a randomized controlled trial (the ACT Trial). Trials. 2020. PMID: 31907024. doi:10.1186/s13063-019-3798-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。